Nicox Stock: 14% Surge Following Positive Clinical Results for NCX 470

Positive Phase 3 Results Unveiled for NCX 470

The biotech company from Sophia Antipolis, Nicox, revealed positive results from the Phase 3 study dedicated to NCX 470, its flagship drug candidate for the treatment of glaucoma. These data were presented at the 2026 annual congress of the American Glaucoma Society, a key event for the global ophthalmological community. NCX 470 is the company's main clinical development program, and this milestone represents a significant step in its regulatory journey. The stock now shows a nearly 57% increase over three months and more than 50% over a year, reflecting a renewed interest in this biotechnology sector stock. The acceleration observed this Tuesday reflects the market's reaction to this clinical advancement, which potentially brings NCX 470 closer to a regulatory submission to health authorities.

Technical Breakthrough in Today's Session

From a technical analysis perspective, today's session marks a strong signal: Nicox's stock price has broken through the resistance at 0.42 euros, which also corresponded to the upper Bollinger band. This breakthrough occurs while the stock is significantly above its 50-day and 200-day moving averages, respectively positioned at 0.34 and 0.33 euros, confirming a bullish trend established over several weeks. The RSI, an indicator measuring the momentum of a stock, is at 64, a high level but still below the overbought threshold set at 70. This suggests that the upward movement still has some room before reaching a technical tension zone. The monthly volatility, at 15.15%, remains moderate for a stock of this capitalization, although the range of today's session might contribute to widening it in the coming days.